These days of drug price cutting will see layoffs across the whole pharma spectrum. Large companies are notoriously wasteful in many respects including artificially inflated workforce. Small companies operate more efficiently. They will all suffer, the large companies through layoffs and small companies by layoffs and going under. Foreign companies would adjust too due to decrease in the US revenues.
Result will be more balanced international landscape with American patients being more fairly treated. Finally! Even if it means fewer opportunities for international leaches.
Like in Biomarin these three groups are mostly responsible for a toxic environment at work. On a surface we are American company, but inside, not so. Like under locust.
No raises in sight in 2025, possibly layoffs. If any promotions, they will be as inflated titles. New layers of titles might be added. Salary reductions? Possibly not.
Patent cliff and projected sales decline would lead to restructuring and personnel reductions. This may not help the stock though. May take a few years for company to recover.
Haven for many underperformers.
Their main occupation is protecting a job. National connections count in hiring and career.
Still it is too big to fail organization.
No autonomy, foolish management focusing on ESG which hurts shareholders, micromanagement, tracking our company vehicles, raises below inflation two years in a row, wasteful focus on diversity instead of merit.
Company has "disposable" mentality towards its employees. They do nothing to engender loyalty or respect, and instead have a "you should be glad we employed you" mentality. To hell with them.
